Skip to main content

Table 3 Multiple Cox and logistic regression analyses for (A) overall survival, (B) progression free survival, and (C) chemotherapy response of clinicopathological parameters, ERα, TRAP1, and the ERα/TRAP1 expression pattern

From: Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium

A) Overall survival

N = 208

Univariate

Multivariate

  

ERα

TRAP1

Combination

Characteristics

HR (CI95%)

p

HR (CI95%)

p

HR (CI95%)

p

HR (CI 95%)

p

Age (per decade)

1.44 (1.21-1.71)

<0.001

1.40 (1.17-1.68)

<0.001

1.42 (1.18-1.71)

<0.001

1.50 (1.24-1.82)

<0.001

Histology (non-serous vs serous)

1.05 (0.57-1.92)

0.874

1.20 (0.64-2.27)

0.555

1.22 0.65-2.29)

0.545

1.33 (0.70-2.52)

0.381

FIGO (IV vs III vs II)

1.96 (1.25-3.06)

0.003

1.39 (0.85-2.25)

0.187

1.38 (0.85-2.24)

0.188

1.39 (0.86-2.27)

0.176

Grade (3 vs 1,2)

1.74 (1.05-2.88)

0.032

0.98 (0.58-1.67)

0.951

1.34 (0.67-1.92)

0.631

0.96 (0.57-1.64)

0.893

Residual tumor (yes vs no)

2.35 (1.54-3.61)

<0.001

1.87 (1.21-2.89)

0.005

1.79 (1.16-2.77)

0.009

1.80 (1.17-2.78)

0.008

Peritoneal Carcinomatosis (yes vs no)

3.01 (1.75-5.16)

<0.001

2.75 (1.56-4.84)

<0.001

2.45 (1.38-4.32)

0.002

2.68 (1.51-4.74)

0.001

ERα (1/2/3 vs 0)

0.56 (0.37-0.84)

0.005

0.51 (0.34-0.77)

0.002

    

TRAP1 (3 vs 0/1/2)

0.63 (0.42-0.94)

0.025

  

0.65 (0.43-0.99)

0.044

  

Combination ERα/TRAP1*

0.49 (0.32-0.75)

0.001

    

0.41 (0.27-0.64)

<0.001

B) Progression free survival

Characteristics

HR (CI95%)

p

HR (CI95%)

p

HR (CI95%)

p

HR (CI 95%)

p

Age (per decade)

1.21 (1.06-1.38)

0.041

1.14 (0.99-1.31)

0.056

1.15 (1.00-1.32)

0.055

1.17 (1.02-1.35)

0.027

Histology (non-serous vs serous)

0.91 (0.55-1.49)

0.701

1.23 (0.72-2.11)

0.453

1.25 (0.73-2.15)

0.416

1.25 (0.72-2.14)

0.428

FIGO (IV vs III vs II)

2.48 (1.69-3.62)

<0.001

1.85 (1.22-2.79)

0.004

1.91 (1.26-2.89)

0.002

1.91 (1.26-2.89)

0.002

Grade (3 vs 1,2)

1.49 (1.03-2.17)

0.035

0.93 (0.62-1.39)

0.721

0.95 (0.64-1.41)

0.794

0.89 (0.59-1.33)

0.559

Residual tumor yes vs no)

1.99 (1.45-2.75)

<0.001

1.56 (1.11-2.18)

0.010

1.55 (1.10-2.17)

0.011

1.56 (1.11-2.18)

0.010

Peritoneal Carcinomatosis (yes vs no)

2.96 (2.01-4.37)

<0.001

2.98 (1.95-4.55)

<0.001

2.92 (1.91-4.47)

<0.001

3.00 (1.96-4.60)

<0.001

ERα (1/2/3 vs 0)

0.84 (0.62-1.15)

0.279

0.80 (0.58-1.11)

0.185

    

TRAP1 (3 vs 0/1/2)

0.87 (0.63-1.18)

0.367

  

0.87 (0.63-1.20)

0.398

  

Combination ERα/TRAP1*

0.79 (0.56-1.12)

0.188

    

0.70 (0.48-1.02)

0.061

C) Chemotherapy response

Characteristics

HR (CI95%)

p

HR (CI95%)

p

HR (CI95%)

p

HR (CI 95%)

p

Age (per decade)

1.33 (1.02-1.74)

0.036

1.42 (1.06-1.9)

0.019

1.43 (1.06-1.91)

0.019

1.57 (1.15-2.15)

0.005

Histology (non-serous vs serous)

0.74 (0.26-2.08)

0.567

0.92 (0.30-2.83)

0.889

0.93 (0.30-2.83)

0.893

0.88 (0.28-2.73)

0.824

FIGO (IV vs III vs II)

2.06 (1.02-4.15)

0.044

1.59 (0.73-3.49)

0.241

1.65 (0.76-3.61)

0.207

1.67 (0.75-3.72)

0.205

Grade (3 vs 1,2)

1.17 (0.56-2.44)

0.683

0.72 (0.32-1.64)

0.437

0.76 (0.33-1.72)

0.505

0.56 (0.23-1.33)

0.188

Residual tumor (yes vs no)

1.96 (1.01-3.80)

0.046

1.35 (0.67-2.75)

0.411

1.43 (0.71-2.91)

0.318

1.36 (0.66-2.81)

0.408

Peritoneal Carcinomatosis (yes vs no)

3.01 (1.32-6.85)

0.009

3.04 (1.25-7.36)

0.014

2.89 (1.19-7.01)

0.018

3.34 (1.34-8.36)

0.009

ERα (1/2/3 vs 0)

0.62 (0.33-1.17)

0.138

0.53 (0.26-1.06)

0.071

    

TRAP1 (3 vs 0/1/2)

0.53 (0.28-1.00)

0.050

  

0.48 (0.24-0.96)

0.037

  

Combination ERα/TRAP1*

0.38 (0.19-0.75)

0.005

    

0.24 (0.11-0.54)

< 0.001

  1. *ERα and/or TRAP1 high vs ERα- and TRAP1 low.
Back to article page

Molecular Cancer

ISSN: 1476-4598